151
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Autoantibodies against complement C1q in patients with Behcet’s disease: association with vascular involvement

, , &
Pages 316-320 | Received 01 Feb 2013, Accepted 27 Mar 2013, Published online: 05 Mar 2014

References

  • Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun. 2010;34(3): J276–J286.
  • Sturfelt G, Truedsson L. Complement in the immunopathogenesis of rheumatic disease. Nat Rev Rheumatol. 2012;8(8): 458–468.
  • Kallenberg CG. Anti-C1q autoantibodies. Autoimmun Rev. 2008;7(8): 612–615.
  • Stoyanova V, Petrova S, Tchorbadjieva M, Deliyska B, Vasilev V, Tsacheva I. New insight into the autoimmunogenicity of the complement protein C1q. Mol Immunol. 2011;48(4): 678–682.
  • Tsirogianni A, Pipi E, Soufleros K. Relevance of anti-C1q autoantibodies to lupus nephritis. Ann N Y Acad Sci. 2009;1173: 243–251.
  • Yin Y, Wu X, Shan G, Zhang X. Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis. Lupus. 2012;21(10): 1088–1097.
  • Brown NA, John D. Carter JD. Urticarial vasculitis. Curr Rheumatol Rep. 2007;9(4):312–9.
  • Hatemi G, Seyahi E, Fresko I, Hamuryudan V. Behçet’s syndrome: a critical digest of the recent literature. Clin Exp Rheumatol. 2012;30(3 Suppl 72): S80–S89.
  • Yazici Y, Yurdakul S, Yazici H. Behcet’s syndrome. Curr Rheumatol Rep. 2010;12(6): 429–435.
  • Bardak Y, Aridoğan BC. The demonstration of serum interleukin 6–8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet’s disease with ocular involvement. Ocul Immunol Inflamm. 2004;12: 53–58.
  • Tüzün E, Kürtüncü M, Türkoğlu R, Içöz S, Pehlivan M, Birişik O, et al. Enhanced complement consumption in neuromyelitis optica and Behçet’s disease patients. J Neuroimmunol. 2011;233(1–2): 211–215.
  • Al-Mutawa SA, Hegab SM. Behcet’s disease. Clin Exp Med. 2004;4: 103–131.
  • Mendoza-Pinto C, García-Carrasco M, Jiménez-Hernández M, Jiménez Hernández C, Riebeling-Navarro C, Nava Zavala A, et al. Etiopathogenesis of Behcet’s disease. Autoimmun Rev. 2010;9(4): 241–245.
  • International Study Group for Behcet’s disease. Criteria for diagnosis of Behcet’s disease. Lancet. 1990;335: 1078–1080.
  • Choe JY, Park SH, Kim SK. Serum angiopoietin-1 level is increased in patients with Behçet’s disease. Joint Bone Spine. 2010;77(4): 340–344.
  • Potlukova E, Kralikova P. Anti-C1q antibodies in theory and in clinical practice. Scand J Immunol. 2008;67(5): 423–430.
  • Braun A, Sis J, Max R, Mueller K, Fiehn C, Zeier M, et al. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases. Scand J Rheumatol. 2007;36(4): 291–298.
  • Sinico RA, Rimoldi L, Radice A, Bianchi L, Gallelli B, Moroni G. Anti-C1q autoantibodies in lupus nephritis. Ann N Y Acad Sci. 2009;1173: 47–51.
  • Horváth L, Czirják L, Fekete B, Jakab L, Prohászka Z, Cervenak L, et al. Levels of antibodies against C1q and 60 kDa family of heat shock proteins in the sera of patients with various autoimmune diseases. Immunol Lett. 2001;75(2): 103–109.
  • Akhter E, Burlingame RW, Seaman AL, Magder L, Petri M. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus. 2011;20(12): 1267–1274.
  • Potlukova E, Jiskra J, Limanova Z, Kralikova P, Smutek D, Mareckova H, et al. Autoantibodies against complement C1q correlate with the thyroid function in patients with autoimmune thyroid disease. Clin Exp Immunol. 2008;153(1): 96–101.
  • Tüzün E, Saini SS, Ghosh S, Rowin J, Meriggioli MN, Christadoss P. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromuscul Disord. 2006;16(2): 137–143.
  • Prohászka Z, Daha MR, Süsal C, Daniel V, Szlávik J, Bánhegyi D, et al. C1q autoantibodies in HIV infection: correlation to elevated levels of autoantibodies against 60-kDa heat-shock proteins. Clin Immunol. 1999;90(2): 247–255.
  • Lienesch DW, Sherman KE, Metzger A, Shen GQ. Anti-Clq antibodies in patients with chronic hepatitis C infection. Clin Exp Rheumatol. 2006;24(2): 183–185.
  • Saadoun D, Sadallah S, Trendelenburg M, Limal N, Sene D, Piette JC, et al. Anti-C1q antibodies in hepatitis C virus infection. Clin Exp Immunol. 2006;145(2): 308–312.
  • Siegert CE, Kazatchkine MD, Sjöholm A, Würzner R, Loos M, Daha MR. Autoantibodies against C1q: view on clinical relevance and pathogenic role. Clin Exp Immunol. 1999;116(1): 4–8.
  • Gamble CN, Wiesner KB, Shapiro RF, Boyer WJ. The immune complex pathogenesis of glomerulonephritis and pulmonary vasculitis in Behçet’s disease. Am J Med. 1979;66(6): 1031–1039.
  • Navratil JS, Watkins SC, Wisnieski JJ, Ahearn JM. The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells. J Immunol. 2001;166(5): 3231–3239.
  • Bigler C, Schaller M, Perahud I, Osthoff M, Trendelenburg M. Autoantibodies against complement C1q specifically target C1q bound on early apoptotic cells. J Immunol. 2009;183(5): 3512–3521.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.